Nyxoah's FDA Approval Lands a Neurostimulator in the Sleep Apnea Patient's Jaw

For the millions of people with moderate-to-severe obstructive sleep apnea, the nightly choice often comes down to a machine or a mask. Continuous positive airway pressure, or CPAP, is the standard first-line therapy, a proven workhorse that can feel anything but restful. The clinical reality is that a significant portion of patients cannot or will not tolerate it long-term, leaving them with a condition linked to cardiovascular risk, stroke, and depression without an effective treatment [Nyxoah, Unknown]. This adherence gap is the patient outcome that Nyxoah, a Belgian medical device company, is built to address. Its answer is a small, battery-free neurostimulator implanted under the chin, designed to keep the airway open by stimulating the tongue's nerve during sleep.

The Genio system's bilateral bet

Nyxoah's flagship product, the Genio system, received FDA Premarket Approval in August 2025, a critical regulatory milestone that unlocked its first U.S. commercial implants [Nyxoah, Aug 2025]. The device is a form of hypoglossal nerve stimulation, a therapy concept that has been validated in the market for nearly a decade by U.S. leader Inspire Medical Systems. Where Nyxoah stakes its technical differentiation is on a bilateral, rather than unilateral, approach. The Genio system's electrode is designed to stimulate both branches of the hypoglossal nerve, which controls tongue movement, with a single implant. The company's thesis is that this design leads to more natural, balanced tongue motion and could potentially treat a broader patient population. The system is also battery-free, powered externally through a wearable patch, which theoretically simplifies the surgical procedure and may reduce long-term hardware complications.

A public company's commercial climb

Founded in 2009 and taken public on the Nasdaq in July 2021, Nyxoah has navigated the long, capital-intensive path typical of a regulated medical device company [Stockanalysis.com, Unknown]. Its financial trajectory shows a commercial operation in early, but accelerating, growth. The company reported net revenue of €10.0 million for the full year 2025, more than double the €4.5 million recorded in 2024 [GlobeNewswire, 2026-03]. The third quarter of 2025 included the first trickle of U.S. revenue, €231,000, from the initial Genio implants following the FDA green light [Stocktitan, 2025-11]. These figures remain modest, underscoring that Nyxoah's story is now one of commercial execution against an established market leader.

2024 Net Revenue | 4.5 | M EUR
2025 Net Revenue | 10.0 | M EUR

The competitive and regulatory landscape

Nyxoah does not have the field to itself. Its path to market share is directly through the installed base and clinical relationships of Inspire Medical Systems, a company with a multi-year head start, deep physician training programs, and revenue measured in hundreds of millions of dollars [Neurotech Reports, Unknown]. Furthermore, the medical device sector is unforgiving of missteps. In April 2025, Nyxoah was the subject of a securities class action investigation related to communications around the FDA's approvable letter for the Genio PMA, a reminder of the intense scrutiny public medtech companies face during regulatory processes [PRNewswire, Businesswire, 2025]. For Nyxoah, the near-term playbook is clear: use its CE Mark in Europe and new FDA approval in the U.S. to train sleep surgeons, secure hospital contracts, and demonstrate not just non-inferiority but a tangible clinical advantage in patient outcomes and ease of use.

The company has structured its leadership to navigate this phase. Olivier Taelman leads as CEO, while the appointment of Dr. Maurits S. Boon as Chief Medical Officer brings over two decades of academic and clinical expertise in sleep surgery directly into the commercial strategy [Nyxoah, Unknown]. Their challenge is multifaceted:

• Clinical adoption. Convincing sleep surgeons, often already trained on a competitor's system, to adopt a new surgical technique and device.
• Reimbursement. Securing consistent insurance coverage, a process that can vary by payer and region, which is crucial for patient access.
• Market education. Differentiating the bilateral, battery-free value proposition in a way that resonates with both physicians and patients.

The standard of care today

For the patient population with moderate-to-severe obstructive sleep apnea who fail CPAP therapy, the current landscape offers limited alternatives. Inspire's hypoglossal nerve stimulator is the dominant invasive option, but it represents a single product in a vast market of untreated need. Other interventions range from oral appliances to more invasive maxillomandibular advancement surgery, each with its own efficacy and tolerance trade-offs. This is the clinical gap Nyxoah is aiming to fill. Its success would not be measured merely in revenue but in expanding the toolbox for sleep physicians and offering a viable, potentially more comfortable, long-term solution to patients for whom the mask and machine are not an answer. The next twelve months will test whether its bilateral bet can translate from a regulatory win into sustained clinical adoption.

Sources

1. [Nyxoah, Unknown] About Nyxoah | https://nyxoah.com/about-nyxoah
2. [Nyxoah, Aug 2025] Nyxoah Update Investor Presentation | https://investors.nyxoah.production.voltaweb.be/sites/default/files/2025-09/20250809_Nyxoah_Update-Investor%20Presentation.pdf
3. [GlobeNewswire, 2026-03] Nyxoah financial report | https://investors.nyxoah.com/sites/default/files/2025-05/Q1%202025%20financial%20report%20(Euronext)%20(ENG)%20-%20FINAL.pdf
4. [Stocktitan, 2025-11] Nyxoah Q3 2025 results | https://stocktitan.com/news/nyxh/nyxoah-reports-third-quarter-2025-financial-results-and-operational-highlights-3k4bq4d5qpsx.html
5. [Stockanalysis.com, Unknown] Nyxoah - Company Profile | https://stockanalysis.com/stocks/nyxh/company/
6. [Neurotech Reports, Unknown] Sleep apnea market | https://www.neurotechreports.com/pages/sleep-apnea-market.html
7. [PRNewswire, Businesswire, 2025] Securities fraud class action investigation | https://www.businesswire.com/news/home/20250403752644/en/The-Schall-Law-Firm-Announces-it-Is-Filing-a-Class-Action-Suit-Against-Nyxoah-S.A.-and-Encourages-Investors-with-Losses-in-Excess-of-100000-to-Contact-the-Firm